Oncomed Manufacturing, a CDMO, is investing in a new production line for syringes. Zuzana Jorová, Marketing & Sales Manager, Oncomed Manufacturing, outlined the company’s expansion plan at the DCAT Member Company Announcement Forum held on March 18th, 2024, at DCAT Week. 

Oncomed Manufacturing, a member of CDMO Medac Group based in Brno, Czech Republic, is commissioning a new line for the production of syringes. The line will complement two vial lines that are already well established. The new line will boost production capacity, enabling the manufacture of over 100 million of 1-mL long syringes per year.

The production line possesses the capability to accommodate small molecules, both high- and low-potent as well as large molecules. Besides small-volume production, which utilizes formats ranging from 0.5 to 3 mL, its capabilities extend to the manufacturing of large-volume syringes, specifically up to 20 mL and 50 mL.

The investment into the new production line and automatic optical inspection line provides the company the ability to meet the growing demand for syringes and to expand Oncomed´s product portfolio. The line will be operational in 2024 with the first product and will offer free capacity from 2025.